Skip to main content
Erschienen in: Die Dermatologie 12/2019

11.11.2019 | Wirkstoffe | Leitthema

Grundlagen der Pharmakologie biologischer Arzneimittel

verfasst von: Prof. Dr. Johannes Wohlrab

Erschienen in: Die Dermatologie | Ausgabe 12/2019

Einloggen, um Zugang zu erhalten

Zusammenfassung

Biologische Arzneimittel sind die Gesamtheit aller Arzneistoffe oder Präparationen aus Arzneistoffen, die biologischen Ursprungs sind oder aus biologischem Material hergestellt werden. Das Spektrum biologischer Arzneimittel ist umfangreich und schließt aus biologischem Material isolierte Stoffe, rekombinante RNA(Ribonukleinsäure)-Moleküle, Proteine sowie Vollantikörper, Antikörperfragmente oder Antikörper-Drug-Konjugate ein. Die Besonderheiten der molekularen Eigenschaften und Funktionen biologischer Arzneistoffe bedingen einen hochkomplexen, variablen Aufbau. Aufgrund der Spezifität beabsichtigter pharmakodynamischer Effekte auf ein komplexes biologisches Regulationssystem sind Besonderheiten bezüglich unerwünschter Effekte, Pharmakokinetik und Sicherheit sowohl regulatorisch als auch klinisch zu beachten.
Literatur
1.
Zurück zum Zitat Heymann WR (2005) Side effects of the biologics. J Am Acad Dermatol 53:692–693CrossRef Heymann WR (2005) Side effects of the biologics. J Am Acad Dermatol 53:692–693CrossRef
2.
Zurück zum Zitat Succaria F, Bhawan J (2017) Cutaneous side-effects of biologics in immune-mediated disorders: A histopathological perspective. J Dermatol 44:243–250CrossRef Succaria F, Bhawan J (2017) Cutaneous side-effects of biologics in immune-mediated disorders: A histopathological perspective. J Dermatol 44:243–250CrossRef
4.
Zurück zum Zitat Ryckaert S, Pardon E, Steyaert J, Callewaert N (2010) Isolation of antigen-binding camelid heavy chain antibody fragments (nanobodies) from an immune library displayed on the surface of pichia pastoris. J Biotechnol 145:93–98CrossRef Ryckaert S, Pardon E, Steyaert J, Callewaert N (2010) Isolation of antigen-binding camelid heavy chain antibody fragments (nanobodies) from an immune library displayed on the surface of pichia pastoris. J Biotechnol 145:93–98CrossRef
5.
Zurück zum Zitat Toleikis L, Frenzel A (2012) Cloning single-chain antibody fragments (ScFv) from hyrbidoma cells. Methods Mol Biol 907:59–71CrossRef Toleikis L, Frenzel A (2012) Cloning single-chain antibody fragments (ScFv) from hyrbidoma cells. Methods Mol Biol 907:59–71CrossRef
6.
Zurück zum Zitat Vaks L, Benhar I (2014) Production of stabilized scfv antibody fragments in the e. Coli bacterial cytoplasm. Methods Mol Biol 1060:171–184CrossRef Vaks L, Benhar I (2014) Production of stabilized scfv antibody fragments in the e. Coli bacterial cytoplasm. Methods Mol Biol 1060:171–184CrossRef
7.
Zurück zum Zitat Chapman AP (2002) Pegylated antibodies and antibody fragments for improved therapy: A review. Adv Drug Deliv Rev 54:531–545CrossRef Chapman AP (2002) Pegylated antibodies and antibody fragments for improved therapy: A review. Adv Drug Deliv Rev 54:531–545CrossRef
8.
Zurück zum Zitat Dahlen E, Veitonmaki N, Norlen P (2018) Bispecific antibodies in cancer immunotherapy. Ther Adv Vaccines Immunother 6:3–17CrossRef Dahlen E, Veitonmaki N, Norlen P (2018) Bispecific antibodies in cancer immunotherapy. Ther Adv Vaccines Immunother 6:3–17CrossRef
9.
Zurück zum Zitat Wang Q, Chen Y, Park J, Liu X, Hu Y, Wang T, McFarland K, Betenbaugh MJ (2019) Design and production of bispecific antibodies. Antibodies 8:antib8030043 Wang Q, Chen Y, Park J, Liu X, Hu Y, Wang T, McFarland K, Betenbaugh MJ (2019) Design and production of bispecific antibodies. Antibodies 8:antib8030043
10.
Zurück zum Zitat Pan W, Cai T, Tang S, Zhou L, Dong J (2018) Trifunctional metasurfaces: concept and characterizations. Opt Express 26:17447–17457CrossRef Pan W, Cai T, Tang S, Zhou L, Dong J (2018) Trifunctional metasurfaces: concept and characterizations. Opt Express 26:17447–17457CrossRef
11.
Zurück zum Zitat Flemming A (2019) Trifunctional antibodies unleash nk cells. Nat Rev Cancer 19:369CrossRef Flemming A (2019) Trifunctional antibodies unleash nk cells. Nat Rev Cancer 19:369CrossRef
12.
Zurück zum Zitat Hedrich WD, Fandy TE, Ashour HM, Wang H, Hassan HE (2018) Antibody-drug conjugates: pharmacokinetic/pharmacodynamic modeling, preclinical characterization, clinical studies, and lessons learned. Clin Pharmacokinet 57:687–703CrossRef Hedrich WD, Fandy TE, Ashour HM, Wang H, Hassan HE (2018) Antibody-drug conjugates: pharmacokinetic/pharmacodynamic modeling, preclinical characterization, clinical studies, and lessons learned. Clin Pharmacokinet 57:687–703CrossRef
14.
Zurück zum Zitat O’Brien J, Hayder H, Zayed Y, Peng C (2018) Overview of microrna biogenesis, mechanisms of actions, and circulation. Front Endocrinol 9:402CrossRef O’Brien J, Hayder H, Zayed Y, Peng C (2018) Overview of microrna biogenesis, mechanisms of actions, and circulation. Front Endocrinol 9:402CrossRef
15.
Zurück zum Zitat Hayes J, Peruzzi PP, Lawler S (2014) Micrornas in cancer: biomarkers, functions and therapy. Trends Mol Med 20:460–469CrossRef Hayes J, Peruzzi PP, Lawler S (2014) Micrornas in cancer: biomarkers, functions and therapy. Trends Mol Med 20:460–469CrossRef
16.
Zurück zum Zitat Ross K (2018) Towards topical microrna-directed therapy for epidermal disorders. J Control Release 269:136–147CrossRef Ross K (2018) Towards topical microrna-directed therapy for epidermal disorders. J Control Release 269:136–147CrossRef
17.
Zurück zum Zitat Doevendans E, Schellekens H (2019) Immunogenicity of innovative and biosimilar monoclonal antibodies. Antibodies 8:antib8010021CrossRef Doevendans E, Schellekens H (2019) Immunogenicity of innovative and biosimilar monoclonal antibodies. Antibodies 8:antib8010021CrossRef
18.
Zurück zum Zitat Hindryckx P, Novak G, Vande Casteele N, Khanna R, Laukens D, Jairath V, Feagan BG (2017) Incidence, prevention and management of anti-drug antibodies against therapeutic antibodies in inflammatory bowel disease: A practical overview. Drugs 77:363–377CrossRef Hindryckx P, Novak G, Vande Casteele N, Khanna R, Laukens D, Jairath V, Feagan BG (2017) Incidence, prevention and management of anti-drug antibodies against therapeutic antibodies in inflammatory bowel disease: A practical overview. Drugs 77:363–377CrossRef
19.
Zurück zum Zitat Thomas LW, Lee EB, Wu JJ (2019) Systematic review of anti-drug antibodies of il-17 inhibitors for psoriasis. J Dermatolog Treat 30:110–116CrossRef Thomas LW, Lee EB, Wu JJ (2019) Systematic review of anti-drug antibodies of il-17 inhibitors for psoriasis. J Dermatolog Treat 30:110–116CrossRef
21.
Zurück zum Zitat Hayakawa T (1999) science of evaluating the characteristics, quality and safety of biotechnological products: Rdna-derived products, cell culture technology-derived products, gene therapy products, cellular therapy products, and transgenic animal-derived protein products and cellular products. Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku 117:1–38 Hayakawa T (1999) science of evaluating the characteristics, quality and safety of biotechnological products: Rdna-derived products, cell culture technology-derived products, gene therapy products, cellular therapy products, and transgenic animal-derived protein products and cellular products. Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku 117:1–38
22.
Zurück zum Zitat EEC note for guidance (1990) Production and quality control of cytokine products derived by biotechnological processes. Ad hoc working party on biotechnology/pharmacy. Pharmacol Toxicol 67:353–358 EEC note for guidance (1990) Production and quality control of cytokine products derived by biotechnological processes. Ad hoc working party on biotechnology/pharmacy. Pharmacol Toxicol 67:353–358
23.
Zurück zum Zitat Note for guidance (1991) Production and quality control of cytokine products derived by biotechnological processes. Committee for proprietary medicinal products: Ad hoc working party on biotechnology/pharmacy and working party on safety medicines. Biologicals 19:125–131CrossRef Note for guidance (1991) Production and quality control of cytokine products derived by biotechnological processes. Committee for proprietary medicinal products: Ad hoc working party on biotechnology/pharmacy and working party on safety medicines. Biologicals 19:125–131CrossRef
24.
Zurück zum Zitat International conference on harmonisation (1998) guidance on quality of biotechnological/biological products: Derivation and characterization of cell substrates used for production of biotechnological/biological products; availability. Notice. Food and drug administration, hhs. Fed Regist 63:50244–50249 International conference on harmonisation (1998) guidance on quality of biotechnological/biological products: Derivation and characterization of cell substrates used for production of biotechnological/biological products; availability. Notice. Food and drug administration, hhs. Fed Regist 63:50244–50249
25.
Zurück zum Zitat Quality of biotechnological products (1998) Derivation and characterisation of cell substrates used for production of biotechnological/biological products. Ich harmonised tripartite guideline. Dev Biol Stand 93:223–234 Quality of biotechnological products (1998) Derivation and characterisation of cell substrates used for production of biotechnological/biological products. Ich harmonised tripartite guideline. Dev Biol Stand 93:223–234
26.
Zurück zum Zitat Quality of biotechnological products (1998) Analysis of the expression construct in cell lines used for production of r‑DNA derived protein products. Ich harmonised tripartite guideline. Dev Biol Stand 93:205–208 Quality of biotechnological products (1998) Analysis of the expression construct in cell lines used for production of r‑DNA derived protein products. Ich harmonised tripartite guideline. Dev Biol Stand 93:205–208
27.
Zurück zum Zitat Quality of biotechnological products (1998) Viral safety evaluation of biotechnology products derived from cell lines of human or animal origin. Ich harmonised tripartite guideline. Dev Biol Stand 93:177–201 Quality of biotechnological products (1998) Viral safety evaluation of biotechnology products derived from cell lines of human or animal origin. Ich harmonised tripartite guideline. Dev Biol Stand 93:177–201
28.
Zurück zum Zitat Quality of biotechnological products (1998) Stability testing of biotechnological/biological products. Annex to the ich harmonised tripartite guideline for the stability testing of new drug substances and products. Dev Biol Stand 93:211–219 Quality of biotechnological products (1998) Stability testing of biotechnological/biological products. Annex to the ich harmonised tripartite guideline for the stability testing of new drug substances and products. Dev Biol Stand 93:211–219
29.
Zurück zum Zitat van Gerven J, Bonelli M (2018) Commentary on the ema guideline on strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products. Br J Clin Pharmacol 84:1401–1409CrossRef van Gerven J, Bonelli M (2018) Commentary on the ema guideline on strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products. Br J Clin Pharmacol 84:1401–1409CrossRef
30.
Zurück zum Zitat Yang Z, Wang H, Salcedo TW, Suchard SJ, Xie JH, Schneeweis LA, Fleener CA, Calore JD, Shi R, Zhang SX, Rodrigues AD, Car BD, Marathe PH, Nadler SG (2015) Integrated pharmacokinetic/pharmacodynamic analysis for determining the minimal anticipated biological effect level of a novel anti-cd28 receptor antagonist bms-931699. J Pharmacol Exp Ther 355:506–515CrossRef Yang Z, Wang H, Salcedo TW, Suchard SJ, Xie JH, Schneeweis LA, Fleener CA, Calore JD, Shi R, Zhang SX, Rodrigues AD, Car BD, Marathe PH, Nadler SG (2015) Integrated pharmacokinetic/pharmacodynamic analysis for determining the minimal anticipated biological effect level of a novel anti-cd28 receptor antagonist bms-931699. J Pharmacol Exp Ther 355:506–515CrossRef
32.
Zurück zum Zitat Wohlrab J (2015) Pharmacokinetic characteristics of therapeutic antibodies. J Dtsch Dermatol Ges 13:530–534PubMed Wohlrab J (2015) Pharmacokinetic characteristics of therapeutic antibodies. J Dtsch Dermatol Ges 13:530–534PubMed
33.
Zurück zum Zitat Toon S (1996) The relevance of pharmacokinetics in the development of biotechnology products. Eur J Drug Metab Pharmacokinet 21:93–103CrossRef Toon S (1996) The relevance of pharmacokinetics in the development of biotechnology products. Eur J Drug Metab Pharmacokinet 21:93–103CrossRef
35.
Zurück zum Zitat Ryman JT, Meibohm B (2017) Pharmacokinetics of monoclonal antibodies. CPT Pharmacometrics Syst Pharmacol 6:576–588CrossRef Ryman JT, Meibohm B (2017) Pharmacokinetics of monoclonal antibodies. CPT Pharmacometrics Syst Pharmacol 6:576–588CrossRef
Metadaten
Titel
Grundlagen der Pharmakologie biologischer Arzneimittel
verfasst von
Prof. Dr. Johannes Wohlrab
Publikationsdatum
11.11.2019
Verlag
Springer Medizin
Erschienen in
Die Dermatologie / Ausgabe 12/2019
Print ISSN: 2731-7005
Elektronische ISSN: 2731-7013
DOI
https://doi.org/10.1007/s00105-019-04502-4

Weitere Artikel der Ausgabe 12/2019

Die Dermatologie 12/2019 Zur Ausgabe

Rezepturtipp für die Praxis aus der Praxis

Wundbehandlung mit Magistralrezepturen

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.